James B. Whitmore
About
James B. Whitmore is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology.
According to data from OpenAlex, James B. Whitmore has authored 63 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 16 papers in Immunology. Recurrent topics in James B. Whitmore's work include Prostate Cancer Treatment and Research (24 papers), Cancer Immunotherapy and Biomarkers (19 papers) and Radiopharmaceutical Chemistry and Applications (10 papers). James B. Whitmore is often cited by papers focused on Prostate Cancer Treatment and Research (24 papers), Cancer Immunotherapy and Biomarkers (19 papers) and Radiopharmaceutical Chemistry and Applications (10 papers). James B. Whitmore collaborates with scholars based in United States, Canada and United Kingdom. James B. Whitmore's co-authors include Jan M. Agosti, Marshelle Warren, Harold S. Nelson, Larry Borish, Abraham Gedalia, Carol A. Wallace, Leonard D. Stein, Edward H. Giannini, James J. Nocton and Norman T. Ilowite and has published in prestigious journals such as New England Journal of Medicine, Circulation and Nature Medicine.
In The Last Decade
James B. Whitmore
63 papers receiving 3.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| James B. Whitmore United States | 25 | 1.5k | 1.3k | 817 | 749 | 726 | 63 | 4.0k | ||
| Alexandre Karras France | 40 | 1.3k 0.9× | 866 0.7× | 227 0.3× | 880 1.2× | 1.2k 1.6× | 164 | 5.1k | ||
| T. Papo France | 44 | 1.6k 1.0× | 1.2k 0.9× | 264 0.3× | 2.1k 2.8× | 1.5k 2.1× | 245 | 6.4k | ||
| Xavier Le Loët France | 42 | 1.4k 0.9× | 1.3k 1.0× | 328 0.4× | 3.3k 4.5× | 295 0.4× | 198 | 5.4k | ||
| Andrew J.K. Östör United Kingdom | 31 | 982 0.6× | 898 0.7× | 321 0.4× | 1.9k 2.6× | 375 0.5× | 131 | 3.8k | ||
| Marc Bijl Netherlands | 49 | 3.4k 2.3× | 674 0.5× | 401 0.5× | 3.4k 4.5× | 555 0.8× | 154 | 6.7k | ||
| Fádi Fakhouri France | 48 | 4.4k 2.9× | 1.8k 1.4× | 198 0.2× | 622 0.8× | 1.0k 1.4× | 180 | 7.9k | ||
| Ramnath Misra India | 34 | 1.2k 0.8× | 872 0.7× | 218 0.3× | 2.1k 2.7× | 600 0.8× | 208 | 3.9k | ||
| A. Mékinian France | 38 | 1.1k 0.7× | 626 0.5× | 365 0.4× | 1.4k 1.9× | 1.2k 1.6× | 231 | 4.4k | ||
| Thomas Barnetche France | 37 | 1.8k 1.1× | 626 0.5× | 857 1.0× | 1.9k 2.5× | 276 0.4× | 124 | 4.6k | ||
| Pia Raanani Israel | 35 | 673 0.4× | 1.6k 1.3× | 878 1.1× | 300 0.4× | 338 0.5× | 305 | 4.2k |
Countries citing papers authored by James B. Whitmore
Since
Specialization
Citations
This map shows the geographic impact of James B. Whitmore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James B. Whitmore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James B. Whitmore more than expected).
Fields of papers citing papers by James B. Whitmore
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by James B. Whitmore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James B. Whitmore. The network helps show where James B. Whitmore may publish in the future.
Co-authorship network of co-authors of James B. Whitmore
This figure shows the co-authorship network connecting the top 25 collaborators of James B. Whitmore. A scholar is included among the top collaborators of James B. Whitmore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James B. Whitmore. James B. Whitmore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Martin, Lisa J., James B. Whitmore, Rhine R. Shen, & Frank Neumann. (2024). T-cell malignancies with anti-CD19 chimeric antigen receptor T-cell therapy. Blood Advances. 8(15). 4144–4148.
2.
Jacobson, Caron A., Javier Muñoz, Fang Sun, et al.. (2023). Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy. 30(1). 77.e1–77.e15.
3.
Whitmore, James B., et al.. (2016). Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials. Clinical Cancer Research. 23(1). 13–20.
4.
GuhaThakurta, Debraj, Nadeem A. Sheikh, Li-Qun Fan, et al.. (2015). Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clinical Cancer Research. 21(16). 3619–3630.
5.
George, Daniel J., Chadi Nabhan, Todd DeVries, James B. Whitmore, & Leonard G. Gomella. (2015). Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy. Cancer Immunology Research. 3(9). 1063–1069.
6.
Small, Eric J., Celestia S. Higano, Philip W. Kantoff, et al.. (2014). Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T. Prostate Cancer and Prostatic Diseases. 17(3). 259–264.
7.
Beer, Tomasz M., Paul F. Schellhammer, John M. Corman, et al.. (2013). Quality of Life After Sipuleucel-T Therapy: Results From a Randomized, Double-blind Study in Patients With Androgen-dependent Prostate Cancer. Urology. 82(2). 410–415.
8.
Schellhammer, Paul F., Gerald W. Chodak, James B. Whitmore, et al.. (2013). Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial. Urology. 81(6). 1297–1302.
9.
Sheikh, Nadeem A., Daniel P. Petrylak, Philip W. Kantoff, et al.. (2012). Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunology Immunotherapy. 62(1). 137–147.
10.
Wesley, Johnna D., James B. Whitmore, James Trager, & Nadeem A. Sheikh. (2012). An overview of sipuleucel-T: Autologous cellular immunotherapy for prostate cancer. Human Vaccines & Immunotherapeutics. 8(4). 520–527.
11.
Gibofsky, Allan, William Palmer, John A. Goldman, et al.. (2005). Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study. Current Medical Research and Opinion. 22(1). 169–183.
12.
Borish, Larry, Harold S. Nelson, Jonathan Corren, et al.. (2001). Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. Journal of Allergy and Clinical Immunology. 107(6). 963–970.
13.
Brites, Carlos, M. Jean Gilbert, D Pedral-Sampaio, et al.. (2000). A Randomized, Placebo‐Controlled Trial of Granulocyte‐Macrophage Colony‐Stimulating Factor and Nucleoside Analogue Therapy in AIDS. The Journal of Infectious Diseases. 182(5). 1531–1535.
14.
Angel, Jonathan B., Kevin P. High, Frank S. Rhame, et al.. (2000). Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. AIDS. 14(4). 387–395.
15.
Borish, Larry, Harold S. Nelson, Miguel J. Lanz, et al.. (1999). Interleukin-4 Receptor in Moderate Atopic Asthma: A Phase I/II Randomized, Placebo-controlled Trial. American Journal of Respiratory and Critical Care Medicine. 160(6). 1816–1823.
16.
Borges, Luís, Robert E. Miller, Jon Jones, et al.. (1999). Synergistic Action of fms-Like Tyrosine Kinase 3 Ligand and CD40 Ligand in the Induction of Dendritic Cells and Generation of Antitumor Immunity In Vivo. The Journal of Immunology. 163(3). 1289–1297.
17.
Skowron, Gail, Daniel S. Stein, George L. Drusano, et al.. (1999). The Safety and Efficacy of Granulocyte‐Macrophage Colony‐Stimulating Factor (Sargramostim) Added to Indinavir‐ or Ritonavir‐Based Antiretroviral Therapy: A Randomized Double‐Blind, Placebo‐Controlled Trial. The Journal of Infectious Diseases. 180(4). 1064–1071.
18.
Meropol, N J, et al.. (1998). Randomized, placebo-controlled, multicenter trial of granulocyte-macrophage colony-stimulating factor as infection prophylaxis in oncologic surgery. Leukine Surgical Prophylaxis Research Group.. Journal of Clinical Oncology. 16(3). 1167–1173.
19.
Lynch, David H., et al.. (1997). Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nature Medicine. 3(6). 625–631.
20.
Diemunsch, Pierre, et al.. (1997). Dolasetron mesilate prevents and treats post-operative nausea and vomiting in female patients undergoing gynaecological surgery via laparoscopy. European Journal of Anaesthesiology. 14(1). 84–85.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Alexandre Karras Breakdown of academic impact, for papers by T. Papo Breakdown of academic impact, for papers by Xavier Le Loët Breakdown of academic impact, for papers by Andrew J.K. Östör Breakdown of academic impact, for papers by Marc Bijl Breakdown of academic impact, for papers by Fádi Fakhouri Breakdown of academic impact, for papers by Ramnath Misra Breakdown of academic impact, for papers by A. Mékinian Breakdown of academic impact, for papers by Thomas Barnetche Breakdown of academic impact, for papers by Pia Raanani